APLT - NASDAQ
Applied Therapeutics, Inc.
$0.91
+0.0000%Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
At a Glance
Live SnapshotApplied Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Applied Therapeutics, Inc. Cash Flow Statement
APLT • NASDAQ
| Applied Therapeutics, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-105.6M | -119.8M | -82.5M | -105.6M | -94M | -45.5M | -16.5M | -4.3M | |
425K | 354K | 443K | 415K | 380K | 23K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 2.6M | 0.0 | 0.0 | 0.0 | |
13.5M | 7.4M | 9.6M | 11.2M | 8M | 6.2M | 272K | 32K | |
4.9M | 58.3M | 3.2M | -404K | -360K | -218K | 3M | 486K | |
2.5M | -1.4M | -8.8M | 3.7M | 5.2M | 3.2M | 2.1M | 569K | |
-84.3M | -55.2M | -78.1M | -90.7M | -78.2M | -36.3M | -11.2M | -3.2M | |
INVESTING ACTIVITIES | ||||||||
(0.0) | (0.0) | -64.2M | -121.6M | -134.7M | -20M | (0.0) | (0.0) | |
0.0 | 13.9M | 77.4M | 134M | 115.2M | 0.0 | 0.0 | 0.0 | |
(0.0) | (13.9M) | (13.2M) | (12.4M) | -19.5M | -20M | (0.0) | (0.0) | |
FINANCING ACTIVITIES | ||||||||
104.7M | 64.5M | 27.8M | 74.4M | 134.1M | 55.7M | 0.0 | 0.0 | |
-311K | -1.9M | -3.3M | -4.7M | -2.1M | 0.0 | 5.6M | 0.0 | |
9.4M | 11.9M | 3.2M | 5M | 4.3M | 3M | -72K | 0.0 | |
113.8M | 74.5M | 27.7M | 74.7M | 136.3M | 56.4M | 26.7M | 6.5M | |
CASH FLOW SUMMARY | ||||||||
29.5M | 33.2M | -37.2M | -3.6M | 38.6M | 102K | 15.5M | 3.3M | |
49.9M | 16.7M | 53.9M | 57.5M | 18.9M | 18.7M | 3.3M | 2K | |
79.4M | 49.9M | 16.7M | 53.9M | 57.5M | 18.9M | 18.7M | 3.3M | |
-84.3M | -55.2M | -78.1M | -90.7M | -78.2M | -36.3M | -11.2M | -3.2M |
SEC Filings
APLT - Filing history and reports
No SEC filings available for APLT
Related Guides
Continue your APLT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.